Arati Desai, MD
Hospice and Palliative Medicine · Philadelphia, PANPI 1689638983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Agios Pharmaceuticals, Inc. accounts for 64.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $185 and has fallen 65.0% since, to $65 in 2025.
Across 4 payments — averaging $71.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$185
- Novocure Inc.$74
- Telix Pharmaceuticals$28
Across 46 payments — averaging $6443.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$114K
- Servier Bioinnovation$78K
- Agios Pharmaceuticals, Inc.$36K
- Servier Pharmaceuticals LLC$35K
- Merck$33K
What the payments were for
- Food & beverage$286100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 1 | $185 |
| Novocure Inc. | 2 | $74 |
| Telix Pharmaceuticals | 1 | $28 |
How this compares
$286 in reported general payments places this provider in the 75th percentile of 73 hospice and palliative medicine providers in Pennsylvania.
See all hospice and palliative medicine providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $10,394 |
| GleostineLomustine | 11 | $10,161 |
| Lacosamide | 39 | $8,026 |
| Levetiracetam | 121 | $2,579 |
| Dexamethasone | 93 | $2,094 |
| Levetiracetam ErLevetiracetam | 13 | $898 |
| Ondansetron Hcl | 58 | $430 |
| Duloxetine Hcl | 14 | $331 |
| Famotidine | 28 | $242 |
| Quetiapine Fumarate | 11 | $111 |
| Gabapentin | 14 | $107 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 30 | $94 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in Philadelphia
- John LiantonioPhiladelphia$795
- Erin KellyPhiladelphia$750
- Eli LevinPhiladelphia$333
- Victoria JohnsonPhiladelphia$293
- Pallavi KumarPhiladelphia$169
- Devashish DesaiPhiladelphia$163
- Michael ScottPhiladelphia$162
- Siobhan KehoePhiladelphia$145
- Heather CurryPhiladelphia$120
- Brenda BuzydlowskiPhiladelphia$69
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.